Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 5, 2013, Pages 601-609

  Shin, K H ^a   Choi, M H ^b   Lim, K S ^a   Yu, K S ^a   Jang, I J ^a   Cho, J Y ^a  

^a Seoul National University   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYMIDAZOLAM; ALPHA HYDROXYMIDAZOLAM; CYTOCHROME P450 3A; DRUG METABOLITE; KETOCONAZOLE; MIDAZOLAM; RIFAMPICIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG URINE LEVEL; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; METABOLOMICS; NORMAL HUMAN; PRIORITY JOURNAL; URINALYSIS;

ADULT; BIOLOGICAL MARKERS; CORTISONE; CYTOCHROME P-450 CYP3A; ENZYME INDUCTION; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; HYDROCORTISONE; HYDROXYCHOLESTEROLS; KETOCONAZOLE; LIVER; MALE; METABOLOMICS; MIDAZOLAM; PHARMACOGENETICS; RIFAMPIN; YOUNG ADULT;

EID: 84886722102     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.128     Document Type: Article

References (35)

1. Li, A.P., Kaminski, D.L. & Rasmussen, A. Substrates of human hepatic cytochrome P450 3A4. Toxicology 104, 1-8 (1995).
2. Watkins, P.B. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4, 171-184 (1994).
3. Rebbeck, T.R., Jaffe, J.M., Walker, A.H., Wein, A.J. & Malkowicz, S.B. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl. Cancer Inst. 90, 1225-1229 (1998).
4. Lamba, J.K., Lin, Y.S., Schuetz, E.G. & Thummel, K.E. Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev. 54, 1271-1294 (2002).
5. Kang, Y.S. et al. The CYP3A4 18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density. Clin. Pharmacol. Ther. 85, 312-318 (2009).
6. Elens, L., Bouamar, R., Hesselink, D.A., Haufroid, V., van Gelder, T. & van Schaik, R.H. The new CYP3A4 intron 6 C>T polymorphism (CYP3A4 22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. Pharmacogenet. Genomics 22, 373-380 (2012).
7. Kukreja, G., Campiani, G., Khurana, J.M., Joshi, B.P. & Grover, S.K. Unexpected formation of hydroxybiphenylmethane derivatives and some new observations on Labat test. Nat. Prod. Res. 20, 1150-1154 (2006).
8. Serruys, P.W. & Kukreja, N. Late stent thrombosis in drug-eluting stents: Return of the 'VB syndrome'. Nat. Clin. Pract. Cardiovasc. Med. 3, 637 (2006).
9. Diczfalusy, U. et al. 4β-hydroxycholesterol is a new endogenous CYP3A marker: Relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet. Genomics 18, 201-208 (2008).
10. Lehmann, J.M., McKee, D.D., Watson, M.A., Willson, T.M., Moore, J.T. & Kliewer, S.A. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 102, 1016-1023 (1998).
11. Schmiedlin-Ren, P., Thummel, K.E., Fisher, J.M., Paine, M.F. & Watkins, P.B. Induction of CYP3A4 by 1 α, 25-dihydroxyvitamin D3 is human cell linespecific and is unlikely to involve pregnane X receptor. Drug Metab. Dispos. 29, 1446-1453 (2001).
12. Wang, K., Chen, S., Xie, W. & Wan, Y.J. Retinoids induce cytochrome P450 3A4 through RXR/VDR-mediated pathway. Biochem. Pharmacol. 75, 2204-2213 (2008).
13. Diczfalusy, U., Nylén, H., Elander, P. & Bertilsson, L. 4ß-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. Br. J. Clin. Pharmacol. 71, 183-189 (2011).
14. Diczfalusy, U., Kanebratt, K.P., Bredberg, E., Andersson, T.B., Böttiger, Y. & Bertilsson, L. 4®-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin. Br. J. Clin. Pharmacol. 67, 38-43 (2009).
15. Bodin, K. et al. Metabolism of 4 ®-hydroxycholesterol in humans. J. Biol. Chem. 277, 31534-31540 (2002).
16. Lütjohann, D. et al. 4®-hydroxycholesterol as a marker of CYP3A4 inhibition in vivo - effects of itraconazole in man. Int. J. Clin. Pharmacol. Ther. 47, 709-715 (2009).
17. Galteau, M.M. & Shamsa, F. Urinary 6®-hydroxycortisol: A validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur. J. Clin. Pharmacol. 59, 713-733 (2003).
18. Aplenc, R. et al. CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia. Br. J. Haematol. 122, 240-244 (2003).
19. Cho, J.H., Joo, Y.H., Kim, M.S. & Sun, D.I. Venous hemangioma of parapharyngeal space with calcification. Clin. Exp. Otorhinolaryngol. 4, 207-209 (2011).
20. Corona, G., Rizzolio, F., Giordano, A. & Toffoli, G. Pharmaco-metabolomics: An emerging "omics" tool for the personalization of anticancer treatments and identification of new valuable therapeutic targets. J. Cell. Physiol. 227, 2827-2831 (2012).
21. Phapale, P.B. et al. An integrative approach for identifying a metabolic phenotype predictive of individualized pharmacokinetics of tacrolimus. Clin. Pharmacol. Ther. 87, 426-436 (2010).
22. Peng, C.C., Templeton, I., Thummel, K.E., Davis, C., Kunze, K.L. & Isoherranen, N. Evaluation of 6ß-hydroxycortisol, 6ß- hydroxycortisone, and a combination of the two as endogenous probes for inhibition of CYP3A4 in vivo. Clin. Pharmacol. Ther. 89, 888-895 (2011).
23. Kanebratt, K.P. et al. Cytochrome P450 induction by rifampicin in healthy subjects: Determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4®-hydroxycholesterol. Clin. Pharmacol. Ther. 84, 589-594 (2008).
24. Conley, A.J. & Bird, I.M. The role of cytochrome P450 17 〈-hydroxylase and 3 ®-hydroxysteroid dehydrogenase in the integration of gonadal and adrenal steroidogenesis via the ⊗ 5 and ⊗ 4 pathways of steroidogenesis in mammals. Biol. Reprod. 56, 789-799 (1997).
25. Miller, K.K., Cai, J., Ripp, S.L., Pierce, W.M. Jr, Rushmore, T.H. & Prough, R.A. Stereo- and regioselectivity account for the diversity of dehydroepiandrosterone (DHEA) metabolites produced by liver microsomal cytochromes P450. Drug Metab. Dispos. 32, 305-313 (2004).
26. Stevens, J.C. et al. Developmental expression of the major human hepatic CYP3A enzymes. J. Pharmacol. Exp. Ther. 307, 573-582 (2003).
27. Clayton, T.A. et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440, 1073-1077 (2006).
28. Clayton, T.A., Baker, D., Lindon, J.C., Everett, J.R. & Nicholson, J.K. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc. Natl. Acad. Sci. USA 106, 14728-14733 (2009).
29. Winnike, J.H., Li, Z., Wright, F.A., Macdonald, J.M., O'Connell, T.M. & Watkins, P.B. Use of pharmaco-metabonomics for early prediction of acetaminopheninduced hepatotoxicity in humans. Clin. Pharmacol. Ther. 88, 45-51 (2010).
30. Stupans, L., Tan, H.W., Kirlich, A., Tuck, K., Hayball, P. & Murray, M. Inhibition of CYP3A-mediated oxidation in human hepatic microsomes by the dietary derived complex phenol, gallic acid. J. Pharm. Pharmacol. 54, 269-275 (2002).
31. Hulst, L.K., Fleishaker, J.C., Peters, G.R., Harry, J.D., Wright, D.M. & Ward, P. Effect of age and gender on tirilazad pharmacokinetics in humans. Clin. Pharmacol. Ther. 55, 378-384 (1994).
32. Kumar, G.N., Walle, U.K. & Walle, T. Cytochrome P450 3A-mediated human liver microsomal taxol 6 alpha-hydroxylation. J. Pharmacol. Exp. Ther. 268, 1160-1165 (1994).
33. Pascussi, J.M., Gerbal-Chaloin, S., Duret, C., Daujat-Chavanieu, M., Vilarem, M.J. & Maurel, P. The tangle of nuclear receptors that controls xenobiotic metabolism and transport: Crosstalk and consequences. Annu. Rev. Pharmacol. Toxicol. 48, 1-32 (2008).
34. Moon, J.Y., Jung, H.J., Moon, M.H., Chung, B.C. & Choi, M.H. Heat-map visualization of gas chromatography-mass spectrometry based quantitative signatures on steroid metabolism. J. Am. Soc. Mass Spectrom. 20, 1626-1637 (2009).
35. Ha, Y.W., Moon, J.Y., Jung, H.J., Chung, B.C. & Choi, M.H. Evaluation of plasma enzyme activities using gas chromatography-mass spectrometry based steroid signatures. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877, 4125-4132 (2009).